Quick answer: There is no fixed course length. GLP-1 medicines treat obesity as a chronic condition, and the effect largely depends on continued treatment — in the STEP 1 trial extension, participants regained roughly two-thirds of their lost weight within a year of stopping. The realistic framing is long-term management with a planned maintenance phase, not a fixed number of months.
Why people expect a course
Most medicine we encounter is finite. Antibiotics for a week, painkillers until it stops hurting. So the natural assumption is that a weight loss medicine works the same way: take it, lose the weight, stop.
Obesity does not behave like that. It behaves like hypertension or type 2 diabetes — a chronic condition where treatment manages the condition rather than curing it. Nobody expects blood pressure to stay down permanently after stopping antihypertensives, but the same logic surprises people here.
What the withdrawal evidence shows
Two trials answer this directly. The STEP 1 trial extension followed participants after semaglutide was withdrawn and found they regained about two-thirds of their lost weight within a year, with cardiometabolic improvements reversing correspondingly. The STEP 4 trial compared continuing semaglutide against switching to placebo after an initial period: those who continued lost a further 7.9%, while those switched to placebo gained 6.9%.
That is as clear as clinical evidence gets. The medicine works while you take it.
Why regain happens
It is not a lack of discipline. When the medication stops, the appetite suppression stops, and hunger returns to something like its previous level — against a body that is now smaller and therefore needs less energy.
On top of that, metabolic adaptation persists. Research following participants of "The Biggest Loser" found resting metabolic rate remained suppressed years afterwards, beyond what smaller body size alone predicted. You are hungrier and burning less, simultaneously.
What this means practically
Plan for the long term before you start:
- Budget for continuation, not just initiation. If you can only afford six months, discuss that upfront — it changes the plan.
- Build the non-drug foundations from day one. Protein intake and resistance training are what carry you through any period off medication, and reviews of GLP-1 therapy identify both as the mitigations for lean-mass loss.
- Discuss maintenance dosing. For some people a lower maintenance dose holds the result, which changes the cost picture.
- Treat the goal weight as the start of a phase, not a finish line.
Legitimate reasons to stop
Side effects you cannot tolerate. Planning a pregnancy — these medicines are not recommended in pregnancy and are generally stopped well beforehand. Cost becoming unsustainable. A clinical complication such as gallbladder disease. Or a considered decision with your doctor that you have reached a point where a trial off treatment is reasonable.
If you do stop, stopping with a plan and continued support produces a very different outcome from stopping abruptly and alone.
The reframe worth making
If you would not be shocked at taking blood pressure medication for years, the same logic applies here. Long-term treatment is not failure. The evidence for what these medicines do beyond weight — a 20% reduction in major adverse cardiovascular events with semaglutide in SELECT, improvement in obstructive sleep apnoea, reduced knee osteoarthritis pain — is evidence for treating an ongoing condition, not a temporary one.
Explore the topic
- GLP-1 weight loss in India
The complete guide to GLP-1 therapy, results and safety for Indian patients.
- Check your GLP-1 eligibility
Find out whether doctor-supervised GLP-1 therapy is clinically appropriate for you.
References
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022 — roughly two-thirds of lost weight regained one year after stopping.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA, 2021 (STEP 4) — continued treatment −7.9% vs +6.9% after switching to placebo.
- Fothergill E et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity, 2016 — resting metabolic rate stays suppressed after large weight loss.
- Neeland IJ et al. Changes in lean body mass with GLP-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 2024 — protein intake and resistance training to protect muscle.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023 (SELECT) — 20% reduction in major adverse cardiovascular events.
This article is for general information and is not a substitute for individual medical advice. Prescription medicines referenced here are regulated in India by the Central Drugs Standard Control Organisation (CDSCO) and are dispensed only against a valid prescription from a registered medical practitioner.
Ready to Start Your Weight Loss Journey?
Get a personalized medical assessment from MetaFit's expert doctors — tailored for the Indian lifestyle.
Book a Free ConsultationOr download the app to get started



